Ozempic Side Effects: Labels, Warnings and What Users Report

Short answer

Ozempic is a brand of semaglutide, a GLP-1 receptor agonist approved for type 2 diabetes (and, under other brands and labels, used for weight management). The side-effect profile is mainly gastrointestinal — nausea, vomiting, diarrhoea, constipation and abdominal pain — especially when treatment starts or the strength changes. Labels also warn about rarer but serious risks such as pancreatitis, gallbladder disease, dehydration-related kidney problems, low blood sugar when combined with some diabetes drugs, and diabetic eye changes. Our semaglutide file is small: 37 published anonymous confessions as of mid-October 2026. That is a self-selected sample of stories, not a clinical rate. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.

What the labels list

Product labelling (FDA prescribing information for Ozempic, and equivalent monographs elsewhere) is the authoritative list of known risks. Common reactions include nausea, vomiting, diarrhoea, abdominal pain and constipation. Other listed effects include decreased appetite, fatigue, dyspepsia and injection-site reactions.

Serious risks called out on labels include inflammation of the pancreas, gallbladder problems including gallstones, acute kidney injury often linked to fluid loss from GI symptoms, hypoglycaemia when used with insulin or sulfonylureas, and complications of diabetic retinopathy in people with existing eye disease. Semaglutide carries a boxed warning about thyroid C-cell tumours seen in rodents; it is not for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

This page summarises public label themes for searchers. It is not a substitute for the full prescribing information or a clinician's advice. If you have severe ongoing abdominal pain, signs of dehydration, vision changes, or symptoms of low blood sugar, seek care.

What anonymous users report here

Our semaglutide file is small: 37 published anonymous confessions as of mid-October 2026. That is a self-selected sample of stories, not a clinical rate. Phrase matches in that file most often land on burping, nausea and vomiting (tied at a few mentions each). Other stories describe constipation, hair shedding after rapid weight change, and appetite suppression that was the goal of treatment. A percentage on a report page is the share of published stories that used a phrase — not the chance that you will get that effect.

Live counts, related confessions and methodology are on the semaglutide side-effects report and the semaglutide hub. Canadians have a separate overview with Health Canada reporting links: Ozempic side effects in Canada.

Ozempic, Wegovy and Rybelsus share an active ingredient

Ozempic, Wegovy and Rybelsus are all semaglutide. They differ in approved use, device and strength ranges, so side-effect class risks overlap even when brand experiences differ. Side-by-side brand context: Wegovy vs Ozempic. Tirzepatide (Mounjaro, Zepbound) is a different molecule with its own report: Mounjaro vs Ozempic, tirzepatide side-effects report.

Related changes people search for

Rapid facial volume change during weight loss is often searched as "Ozempic face" — see Ozempic face. Shedding after fast weight change is covered on Ozempic hair loss. Neither nickname is a medical diagnosis; both are discussed as weight-loss and nutrition effects more than as unique drug toxicity in most clinical commentary.